Stock Track | GENSCRIPT BIO Plummets 5.26% Intraday on Post-ASCO Profit-Taking and Sector Weakness

Stock Track06-01 11:17

GENSCRIPT BIO's stock plummeted 5.26% during intraday trading on Monday, extending recent declines as investors continued to take profits following the digestion of a key catalyst.

The decline represents a continuation of profit-taking after the ASCO annual meeting catalyst. GenScript's associate company Legend Biotech had presented multiple research results at the ASCO conference, including Phase 1 clinical data for a DLL3-targeting CAR-T therapy for relapsed or refractory small cell lung cancer, alongside new CARVYKTI data. This news had previously driven the stock higher, but subsequent sessions have seen sustained selling pressure as the positive catalyst was fully priced in.

Adding to the downward pressure, Hong Kong Stock Connect channels recorded consecutive large-scale net outflows in recent sessions, raising concerns that institutional investors leveraged the ASCO rally to reduce their positions. At the sector level, the broader Life Sciences Tools and Services space also weakened, amplifying the drag on GenScript's stock performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1112786960?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 11:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112786960","market":"us","top_or_hot":-1,"title":"Stock Track | GENSCRIPT BIO Plummets 5.26% Intraday on Post-ASCO Profit-Taking and Sector Weakness","media":"Stock Track","content":"<p>GENSCRIPT BIO's stock plummeted 5.26% during intraday trading on Monday, extending recent declines as investors continued to take profits following the digestion of a key catalyst.</p><p>The decline represents a continuation of profit-taking after the ASCO annual meeting catalyst. GenScript's associate company Legend Biotech had presented multiple research results at the ASCO conference, including Phase 1 clinical data for a DLL3-targeting CAR-T therapy for relapsed or refractory small cell lung cancer, alongside new CARVYKTI data. This news had previously driven the stock higher, but subsequent sessions have seen sustained selling pressure as the positive catalyst was fully priced in.</p><p>Adding to the downward pressure, Hong Kong Stock Connect channels recorded consecutive large-scale net outflows in recent sessions, raising concerns that institutional investors leveraged the ASCO rally to reduce their positions. At the sector level, the broader Life Sciences Tools and Services space also weakened, amplifying the drag on GenScript's stock performance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GENSCRIPT BIO Plummets 5.26% Intraday on Post-ASCO Profit-Taking and Sector Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GENSCRIPT BIO Plummets 5.26% Intraday on Post-ASCO Profit-Taking and Sector Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-01 11:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GENSCRIPT BIO's stock plummeted 5.26% during intraday trading on Monday, extending recent declines as investors continued to take profits following the digestion of a key catalyst.</p><p>The decline represents a continuation of profit-taking after the ASCO annual meeting catalyst. GenScript's associate company Legend Biotech had presented multiple research results at the ASCO conference, including Phase 1 clinical data for a DLL3-targeting CAR-T therapy for relapsed or refractory small cell lung cancer, alongside new CARVYKTI data. This news had previously driven the stock higher, but subsequent sessions have seen sustained selling pressure as the positive catalyst was fully priced in.</p><p>Adding to the downward pressure, Hong Kong Stock Connect channels recorded consecutive large-scale net outflows in recent sessions, raising concerns that institutional investors leveraged the ASCO rally to reduce their positions. At the sector level, the broader Life Sciences Tools and Services space also weakened, amplifying the drag on GenScript's stock performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1112786960","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112786960","pubTimestamp":1780283846,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"GENSCRIPT BIO's stock plummeted 5.26% during intraday trading on Monday, extending recent declines as investors continued to take profits following the digestion of a key catalyst.The decline...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"个股追踪|金斯瑞生物盘中暴跌5.26%受ASCO后获利了结及板块疲软影响","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"GENSCRIPT BIO's stock plummeted 5.26% during intraday trading on Monday, extending recent declines as investors continued to take profits following the digestion of a key catalyst.The decline represents a continuation of profit-taking after the ASCO annual meeting catalyst. GenScript's associate company Legend Biotech had presented multiple research results at the ASCO conference, including Phase 1 clinical data for a DLL3-targeting CAR-T therapy for relapsed or refractory small cell lung cancer, alongside new CARVYKTI data. This news had previously driven the stock higher, but subsequent sessions have seen sustained selling pressure as the positive catalyst was fully priced in.Adding to the downward pressure, Hong Kong Stock Connect channels recorded consecutive large-scale net outflows in recent sessions, raising concerns that institutional investors leveraged the ASCO rally to reduce their positions. At the sector level, the broader Life Sciences Tools and Services space also weakened, amplifying the drag on GenScript's stock performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1112786960","isCrawlerRequest":true}